Track Rapport Therapeutics's total revenue ($20M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Rapport Therapeutics (RAPP) currently reports a total revenue of $20M as of June 2026. In the prior-year period, the figure was $0. That is below the sector sector average of $1.3B. Use the charts on this page to explore Rapport Therapeutics's total revenue history and peer comparisons.
Rapport Therapeutics's total revenue changed from $0 to $20M (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Rapport Therapeutics's total revenue of $20M is lower than the its sector sector average of $1.3B. That is roughly 98.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Rapport Therapeutics reported $20M in total revenue as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total revenue of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $1.3B. From there, open related valuation or income-statement pages for Rapport Therapeutics, and consider following RAPP for alerts when major investors trade the stock.